R&D The post-Covid New Normal: a golden opportunity for the NHS? I recently had the pleasure of attending the PING Conference 2022, which had the tagline of ‘
Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Views & Analysis UK pharma denied legal challenge to drugs bill cap - updated Rejection of legal challenge an embarrassing blow, and means NHS England free to introduce new budget curbs.
Views & Analysis Improved access? The reality of the PPRS Keeping the UK branded medicines bill within affordable limits - has PPRS delivered?
Views & Analysis Creating headroom: can cutting spend on low-value prescripti... Can reducing NHS spending on 'low-value' prescriptions help fund new drugs?
News Akebia joins GSK in US market for oral CKD anaemia drugs The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.